Phase II Study of Temozolomide for Relapsed Sensitive or Refractory Small Cell Lung Cancer

被引：0
|
作者：
Pietanza, M. Catherine [1 ]
Travis, William D. [1 ]
Chan, Timothy A. [1 ]
Ginsberg, Michelle S. [1 ]
Kris, Andrei Holodny Mark G. [1 ]
Krug, Lee M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
PANCREAS | 2010年 / 39卷 / 02期
关键词：
D O I：
10.1097/01.mpa.0000363940.51906.5a
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：279 / 279
页数：1
相关论文
共 50 条
  • [21] A phase II trial of pazopanib in relapsed/refractory small cell lung cancer (SCLC).
    Gandhi, Leena
    Heist, Rebecca Suk
    Lucca, Joan Vern
    Temel, Jennifer S.
    Fidias, Panos
    Morse, Linda K.
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer
    Lammers, Philip E.
    Shyr, Yu
    Li, Chung-I
    Hutchison, Anne Smith
    Sandler, Alan
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Horn, Leora
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (04) : 559 - 562
  • [23] Temozolomide in combination with either veliparib or placebo in patients with relapsed-sensitive or refractory small-cell lung cancer
    Lazzari, Chiara
    Gregorc, Vanesa
    Bulotta, Alessandra
    Dottore, Alessia
    Altavilla, Giuseppe
    Santarpia, Mariacarmela
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S329 - S333
  • [24] PHASE II STUDY OF WEEKLY AMRUBICIN IN PATIENTS WITH REFRACTORY OR RELAPSED NON-SMALL CELL LUNG CANCER
    Iwasaku, Masahiro
    Nishiyama, Akihiro
    Watanabe, Naoki
    Kunimasa, Kei
    Tsubouchi, Kazuya
    Oka, Saori
    Yoshioka, Hiroshige
    Kitagawa, Chiyoe
    Saka, Hideo
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S875 - S875
  • [25] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Venepalli, N. K.
    Hutchison, A. S.
    Carbone, D. P.
    Johnson, D. H.
    Keedy, V. L.
    Pao, W.
    Sandler, A.
    Horn, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [26] A phase II study of second-line bendamustine in relapsed or refractory small cell lung cancer (SCLC)
    Lovly, Christine Marie
    Li, Chung-I
    Hutchison, Anne Smith
    Carbone, David Paul
    Johnson, David H.
    Keedy, Vicki Leigh
    Pao, William
    Sandler, Alan
    Horn, Leora
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [27] Combination chemotherapy with irinotecan and ifosfamide as second-line treatment of refractory or sensitive relapsed small cell lung cancer: A phase II study
    Ichiki, M
    Gohara, R
    Rikimaru, T
    Kitajima, T
    Fujiki, R
    Shimada, A
    Aizawa, H
    CHEMOTHERAPY, 2003, 49 (04) : 200 - 205
  • [28] Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer
    Hoang, T
    Kim, KM
    Jaslowski, A
    Koch, P
    Beatty, P
    McGovern, J
    Quisumbing, M
    Shapiro, G
    Witte, R
    Schiller, JH
    LUNG CANCER, 2003, 42 (01) : 97 - 102
  • [29] Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer
    Hensing, Thomas A.
    Hanna, Nasser H.
    Gillenwater, Heidi H.
    Camboni, M. Gabriella
    Allievi, Cecilia
    Socinski, Mark A.
    ANTI-CANCER DRUGS, 2006, 17 (06) : 697 - 704
  • [30] Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer
    Schuette, Wolfgang
    Nagel, Sylke
    Juergens, Stefan
    Bork, Ines
    Wollschlaeger, Bettina
    Schaedlich, Steffen
    Blankenburg, Thomas
    CLINICAL LUNG CANCER, 2005, 7 (02) : 133 - 137
12345